VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
-1.44%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$658M
AUM Growth
+$658M
(+447%)
Cap. Flow
+$526M
Cap. Flow
% of AUM
79.91%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
4
Increased
–
Reduced
3
Closed
–
Top Buys
| 1 |
ALX Oncology
ALXO
|
$366M |
| 2 |
Harmony Biosciences
HRMY
|
$119M |
| 3 |
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
|
$42.3M |
| 4 |
MTCR
Metacrine, Inc. Common Stock
MTCR
|
$31.2M |
Top Sells
| 1 |
Akero Therapeutics
AKRO
|
$21.7M |
| 2 |
Precision BioSciences
DTIL
|
$9.2M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$1.61M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ALX Oncology
ALXO
$62.7M
| $366M | 55.63% | +9,699,925 | New | +$366M |
|
|
2
Harmony Biosciences
HRMY
$2.12B
| $119M | 18.06% | +3,504,624 | New | +$119M |
|
|
3
Akero Therapeutics
AKRO
$3.74B
| $75.3M | 11.44% | 2,444,311 -705,708 | -22% | -$21.7M |
|
|
CMPI
4
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $42.3M | 6.43% | +3,673,374 | New | +$42.3M |
|
|
MTCR
5
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $31.2M | 4.75% | +3,059,123 | New | +$31.2M |
|
6
Apellis Pharmaceuticals
APLS
$3.48B
| $15.1M | 2.3% | 501,584 | – | – |
|
|
7
Precision BioSciences
DTIL
$57.8M
| $8M | 1.22% | 1,298,191 -1,493,387 | -53% | -$9.2M |
|
|
VRNA
8
Verona Pharma
VRNA
$9.16B
| $1.24M | 0.19% | 199,075 -257,695 | -56% | -$1.61M |
|